xCures to showcase the value of its healthcare data platform at the 2024 ASCO Annual Meeting

xCures’ patient-centric platform enables outcomes monitoring and evidence generation, providing insights into the best treatments, including for rare cancers.

xCures, a leading-edge healthcare technology company, is pleased to announce the presentation of two abstracts at the American Society of Clinical Oncology (ASCO) Annual Meeting 2024, to be held May 31 – June 4, at McCormick Place, Chicago, IL, USA.

The two abstracts illustrate the value of xCures’ real-time healthcare data platform. The platform’s enhanced longitudinal nationwide data goes beyond traditional retrospective real-world data, allowing for analysis of electronic medical records from partnerships with sites of care nationwide. Through its platform and patient- and observation-driven real-time datasets, xCures helps partners learn from complex and multidisciplinary therapeutic approaches to provide valuable insights to improve outcomes.

“Access to real-time, longitudinal, uninterrupted clinical data offers an unparalleled capacity to extract insights from patient medical records,” said Tim Stuhlmiller, Vice President of Scientific and Medical Affairs at xCures. “These abstracts showcase the importance of our partnerships and our platform’s incredible power to analyze outcomes and support evidence-based decisions, resulting in improved patient care.”

In one work, xCures and their partner Genome Medical, a nationwide telehealth provider of genetic services, analyzed data from patients with germline genetic testing followed by genetic counseling, including cancer risk assessment. The platform generated structured clinical data from multiple care sites to determine the percentage of patients who underwent bilateral mastectomies after receiving genetic testing and genetic counseling from Genome Medical. This is one of the first studies to use multi-institution real-world data to assess the impact of genetic counseling and genetic testing.

Half of the patients with a genetic test result that indicated bilateral mastectomy elected to have a mastectomy done after discussing this guideline-based care option with a Genome Medical genetic counselor. As evidenced in prior research, bilateral mastectomy markedly reduces the risk of breast cancer.

“Access to longitudinal records across multiple care sites allowed us to more thoroughly assess how genetic counseling and genetic testing increase the uptake of guideline-recommended cancer prevention services,” said Colleen Caleshu, Senior Director of Clinical Research at Genome Medical. “Our goal is to make genetics clinically actionable so patients can make more informed decisions about their health. By working with xCures, we are able to gain better insights into those decisions and the impact they have on the patients we serve.”

In the other abstract, xCures partnered with the FibroFighters Foundation to better understand the landscape of real-world treatments for Fibrolamellar carcinoma (FLC) by tracking treatments, molecular profiling, and outcomes. This is essential for such a rare form of liver cancer without an established standard of care.

Patients with FLC undergo extensive molecular profiling with multiple novel therapeutic regimens employed in real-world practice. Raw imaging scans are being aggregated for central radiological review to measure the depth and duration of response offered by the recorded therapeutic strategies. This dataset is a rich resource for academic and government researchers to fuel research and define optimal treatment modalities. Topline statistics for the dataset are available at https://xcures.com/flcdashboard/.

“xCures has done what no one else has been able to do for rare diseases, specifically for Fibrolamellar Carcinoma,” said Paul Kent, MD, Medical Director of the FibroFighters Foundation. “We have the largest interactive, real-time scientific database of FLC ever collected, allowing doctors from 15 countries and 27 institutions to discuss their cases with expert FLC panelists of oncologists, surgeons, radiation oncologists, interventional radiologists, and patient advocates. xCures has driven the most important advances in clinical research for FLC ever.”

Attendees of the ASCO Annual Meeting are encouraged to find Mika Newton, Max Goldstein, Tim Stuhlmiller, or Artem Petrov from xCures, who can provide in-depth insights, discuss potential collaborations, and showcase case studies from the platform’s implementation.

The abstracts presented:

Use of a nationwide, patient-powered observational platform to define the landscape of treatment, molecular profiling, and outcomes for fibrolamellar carcinoma.
Authors: Paul Kent, Alaa Awawda, Hiba Kouser, Alanis Sabates, Zachariah Cole, Mark Shapiro, Tom Stockwell, Timothy Stuhlmiller

https://meetings.asco.org/abstracts-presentations/235938

and,

Leveraging real-world data from multiple institutions to assess the rate of bilateral mastectomy after cancer genetics evaluations with genetic counselors.
Authors: Ashley Daley, Callan Russell, Timothy Stuhlmiller, Zachary Kaufman, Jill Davies, Colleen Caleshu

https://meetings.asco.org/abstracts-presentations/231790

About xCures

Launched in 2018, xCures Inc. operates an AI-assisted platform that automatically retrieves and aggregates medical records from any US care site. Data is extracted and structured within 15 minutes to offer a sophisticated view of a patient’s fully longitudinal health journey, which encompasses everything from genomics to social determinants of health.

Through a variety of tools and data products, xCures provides clinically actionable, real-time insights that facilitate clinical research and care for patients, providers, and partners. For more information, contact info@xcures.com.

xCures Announces Issuance of Groundbreaking Patent

USPTO awards patent for AI tech enabling virtual trials, enhancing clinical decisions through continuous learning from patient experiences.

OAKLAND, CA — xCures, Inc., a leader in health technology, is proud to announce that the U.S. Patent and Trademark Office (USPTO) has officially issued Patent No. 11,887,738, a landmark achievement in biomedical decision-making. This patent marks a significant milestone in the company’s journey to transform the value of healthcare data using artificial intelligence (AI) and deliver on the promise of precision medicine.

The newly patented technology, titled “Platforms for Conducting Virtual Trials,” introduces a novel platform for capturing clinical cases and expert-derived treatment rationales using AI to facilitate biomedical decision-making, which can include virtual clinical trials that continuously learn from the experiences of all patients, on all treatments and all the time. Algorithms such as Bayesian machine learning methods can be applied to coordinate such virtual trials. This invention demonstrates xCures’ vision for transforming US healthcare data into continuous, real-time, regulatory-grade data that can improve care, drive innovation, and accelerate the development of new treatments.

“We’re incredibly excited about this patent. The USPTO recognized our innovative work in AI-enabled learning systems using medical records plus AI to create patient case summaries, using natural language processing to create knowledge bases that support treatment selection, leveraging machine learning for personalized treatment recommendations, incorporating expert human feedback to refine algorithms, and continuous improvements via calibration from real-world outcomes data. It is just the first of many patent-pending innovations in our pipeline,” said Mark Shapiro, Chief Operating Officer at xCures.

With the issuance of this patent, xCures solidifies its position at the forefront of health data and technology. The company is dedicated to leveraging this patented technology to enable stakeholders across the healthcare continuum to implement platforms that collect, aggregate, organize, and structure healthcare data.  This approach enables continuous learning from the treatment of all patients using an AI-based platform.

The patent can be found here.

About xCures

Launched in 2018, xCures Inc. operates an AI-assisted platform that automatically retrieves and aggregates medical records from any US care site. Data is extracted and structured within 15 minutes, to offer a sophisticated view of a patient’s fully longitudinal health journey that encompasses everything from genomics to social determinants of health.

Through a variety of tools and data products, xCures provides clinically actionable, real-time insights that facilitate clinical research and care for patients, providers, and partners. For more information, contact info@xcures.com.

xCures Unveils Expanded AI Health Data Platform: Now Supporting All Therapeutic Areas and is Available as SaaS

The company’s platform expansion transforms the value of US healthcare data by harnessing real-time, regulatory-grade data in any therapeutic area to efficiently understand the complex medical histories of patients and drive research through detailed, longitudinal datasets.

OAKLAND, CA – January 31, 2024 xCures, a trailblazer in healthcare technology, announced today the expansion of its AI-assisted medical data platform to support real-time, regulatory-grade data in any therapeutic area. Originally designed as a tool focused specifically on cancer, the company’s platform expansion now serves as a comprehensive tool to collect and understand medical records for any US patient with any condition.

Harnessing AI/ML technology, xCures’ platform gathers records, extracts, and aggregates data, including organizing and structuring clinical, genomic, and imaging information from diverse sources, into a searchable digital record. This solution can help any user looking to quickly find or assess key clinical information about a patient for care-related activities. This integrated approach transforms how medical professionals and researchers can understand complex patients and cohort characteristics

xCures makes this technology available through software licenses to the platform and direct API connections embedded within existing healthcare workflow management platforms.  The system offers a patient-centric, longitudinal perspective crucial for informed decision-making.  

This evolution marks another advancement that will significantly benefit those making data-driven healthcare decisions.  Because the collected data can also be de-identified it can be be available for secondary research;  xCures provides the most comprehensive patient-centric longitudinal data in the form of deidentified real-world datasets that contain comprehensive insights across all providers and care locations. 

“Expanding our AI platform beyond oncology marks a significant milestone in our mission to transform the value of healthcare data,” said Mika Newton, CEO of xCures. “We’re providing access to a software platform that generates precise real-world data at the individual and cohort levels across all diseases that will accelerate groundbreaking research across many fields and directly benefit patients. ”

With its ability to aggregate and interpret diverse medical records quickly and accurately, xCures’ platform is a game-changer for anyone working to access and interpret retrospective and prospective healthcare or real-world data. It facilitates an in-depth understanding of medical patterns and conditions and enhances the scope of clinical trials and research across various diseases. Making this technology available across the healthcare ecosystem as a platform solution transforms the opportunity to leverage US healthcare data.

For more information, visit https://xcures.com/ 

About xCures

Launched in 2018, xCures Inc. operates an AI-assisted platform that automatically retrieves and aggregates medical records from any US care site. Data is extracted and structured within 15 minutes, to offer a sophisticated view of a patient’s fully longitudinal health journey that encompasses everything from genomics to social determinants of health.

Through a variety of tools and data products, xCures provides clinically actionable, real-time insights that facilitate clinical research and care for patients, providers, and partners. For more information, contact info@xcures.com or visit http://www.xcures.com.

###

xCures and Aetion® Further Enhance Partnership with Rich Real-World Datasets

Partnership now includes access to five comprehensive oncology datasets, enhancing real-world evidence in cancer research.

In the realm of oncology research, diverse, comprehensive, and fully longitudinal datasets are invaluable. They offer a granular view of patient journeys throughout the US, enabling researchers to draw clinically relevant insights.

These comprehensive datasets are crucial for advancing personalized treatment strategies and improving patient outcomes in cancer care.

The challenge in current oncology outcomes research lies in the fragmentation of patient data across numerous healthcare providers and sites of care. This creates significant gaps in understanding patient outcomes and treatment efficacies. The scattered data landscape hinders the development of robust real-world evidence (RWE) necessary for impactful cancer research.

xCures consolidates and structures clinical, genomic, and imaging data directly from patients’ electronic medical records, healthcare providers, and other sites of care along the patient’s care journey.

The broad, longitudinal, patient-centric view enables researchers and clinicians to access up-to-date and comprehensive information, paving the way for more informed and timely treatment decisions.

In addition to contributing data to support Aetion’s collaboration with the Food and Drug Administration, the new partnership enables Aetion®, a global leader in RWE and analytics, to incorporate xCures’ breast cancer, glioma, melanoma, colorectal cancer, and ovarian/uterine cancer datasets into their Accelerated Access Oncology Program.

“We’re thrilled about this partnership with Aetion,” said Mika Newton, xCures CEO. “It’s a testament to the power of collaborative efforts in advancing oncology research. By bringing our real-time, regulatory-grade, clinical data (RRC) to a broader audience, we’re not just sharing information – we’re empowering a shift towards more effective, patient-centric cancer treatments.”

Wendy Turenne, Senior Vice President, Real World Data & Operations at Aetion, said: “We are delighted to partner with xCures, as their datasets provide a unique lens into the patient’s experience. In combination with Aetion® Substantiate, these data can be analyzed in novel ways and shorten the time to generate and deliver critical insights that will help shape the future of cancer treatment.”

Contact us today for more information on how this partnership can empower your research and development strategies.

About xCures

Since 2018, xCures Inc. has operated an AI-assisted platform that automatically retrieves and aggregates medical records from all US care sites. Data is extracted and structured within 15 minutes to offer a sophisticated view of a patient’s fully longitudinal health journey that encompasses everything from genomics to social determinants of health.

Through a variety of tools and data products, xCures provides clinically actionable, real-time insights that facilitate clinical research and care for patients, providers, and partners. For more information, contact info@xcures.com, or visit http://www.xcures.com.

About Aetion®

Aetion is a healthcare analytics company that delivers real-world evidence for the manufacturers, purchasers, and regulators of medical treatments and technologies. Aetion’s suite of real-world data analytics applications analyzes data from the real world to produce transparent, rapid, and scientifically validated answers on safety, effectiveness, and value. Founded by Harvard Medical School faculty members with decades of experience in epidemiology and health outcomes research, Aetion informs healthcare’s most critical decisions—what works best, for whom, and when—to guide product development, commercialization, and payment innovation. Learn more at aetion.com and follow us at @aetioninc.